%20LIMITED%2017-Sep-2007_files/image002.jpg){kind=small}
MIRA
INFORM REPORT
|
Report Date : |
17.09.2007 |
IDENTIFICATION DETAILS
|
Name : |
REKO PHARMACAL (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
13th
K.M., |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1961 |
|
|
|
|
Com. Reg. No.: |
0001355 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
COMPANY NAME
REKO PHARMACAL (PRIVATE) LIMITED
Address
|
Registered Address & Factory |
|
13th K.M., |
|
Tel |
92 (42) 5421203, 5421201 |
|
Fax |
92 (42) 5411533 |
|
|
Short Description Of
Business
|
Nature of Business |
Manufacture & Marketing
of Pharmaceutical Products |
|
Year Established |
1961 |
|
Registration # |
0001355 |
Branch Offices
|
In |
Auditors
|
Azhar Zafar & Co. (Chartered Accountants) |
Legal Status
|
Subject Company was incorporated as a Private Limited Company in 1961 |
Authorized Capital
Rs. 20,000,000/- divided into 200,000 shares of
Rs. 100/- each
Issued & Paid up Capital
Rs.
2,122,800/- divided into 21,228 shares of Rs. 100/- each
Details of Directors
|
Names |
Nationality |
Occupation |
Designation |
|
Mr. Mian Khalid Mansur Mrs. Sadiqa Mansur Mr. Khalid S. Mian Mrs. Seemal Khalid Mian |
Pakistani Pakistani Pakistani Pakistani |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
|
Names of Shareholders |
|
Mr. Mian Khalid Mansur Mrs. Sadiqa Mansur Mr. Khalid S. Mian Mrs. Seemal Khalid Mian |
Associated Companies
|
None |
Products
APSIN, BENIL, BETAMETHASONE, CEFTO, CLOMOCITE, CONCID, DEKOMYCIN, FORTIS, GENICOL, GLYGOL, GONAPAN-M, HYPOTIN, ISORNIT, KENZOL, KETO, LAXONIL, LUCID, MEGAPOL, MEPOL, NEPEXEN, NOCTS, PARA+PLUS, PARA-250, PIROX, PROVATE, PROVATE-G, RAKITAC, RECLOR, REKABSON, REKIRON, REKOCIPRIN, REKOMYCIN, REKOPLEX FORTE, REKOSPORIN, REKOZOL, REKTONIL, RELICATE, REMPACIN, REVITON, REVOCIN, REXOTIL, REZOXIN, RUKGASEE, RUPHEN, SOFAC, TOBIN, VALPRO
Number of Employees
275
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2006 |
400,000,000/- (Estimated) |
Exporting Countries
|
Mainly to Far East & Middle East Countries |
Annual Production
Volume
|
The capacity and production of the company’s plant is
indeterminable as it is multi-product and involves various processes of
manufacture. |
Trade Suppliers
(Foreign)
|
(1) ADANI
PHARMACHEM PVT LTD, (2) LUOTIAN HONGYUAN BIOCHEMICAL CO. LTD, |
Collaboration with
Multinational Companies
|
(1) MAY & BAKER. (2) WYETH LABORATORIES. (3)SAFRON PHARMACEUTICALS. (4) MCJHON PHARMACEUTICALS. (5) GENETICS PHARMACEUTICALS. |
Distributors Network
|
Mainly in all major cities of |
Bankers
MCB Bank Limited,
Faysal Bank Limited,
The Bank of
Habib Bank Limited,
Habib Metropolitan Bank Limited,
Standard Chartered
Memberships
Foreign Exchange
Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 60.72 |
|
|
1 |
Rs. 121.60 |
|
Euro |
1 |
Rs. 84.00 |
Comments
Subject is a well-established company having fine track. Directors are reported as experienced and resourceful businessmen. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms and conditions.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)